SUPRATHEL (HCPCS code A2012) and SUPRA SDRM (HCPCS code A2011) are included on the latest Group 2 Covered Codes by three Medicare Administrative Contractors – Novitas, FCSO, and CGS

Due to PMI’s proven scientific and robust peer-reviewed published clinical evidence and FDA 510(k) regulatory status, three Medicare Administrative Contractors (MACs) – Novitas, FCSO, and CGS – are including both Suprathel and SupraSDRM on their Group 2 Covered Codes List included in their Local Coverage Determinations (LCDs) and associated Local Coverage Articles (LCAs). PMI is thrilled that Suprathel and SupraSDRM will continue to be accessible to more patients across the U.S.

These MACs positively impact ~14 million Medicare beneficiaries in these states:

• Novitas States: Arkansas, Colorado, New Mexico, Oklahoma, Texas, Louisiana, Mississippi, Delaware, District of Columbia, Maryland, New Jersey, Pennsylvania (includes Part B for counties of Arlington and Fairfax in Virginia and the city of Alexandria in Virginia)
• FCSO States: Florida, Puerto Rico, U.S. Virgin Islands
• CGS States: Kentucky, Ohio

These coverage updates for each of these MACs will be effective September 17, 2023. Previous LCDs and LCAs remain in effect until September 16, 2023.

For more information about Suprathel and SupraSDRM, please contact your local representative or info.usa@polymedics.com.

For reimbursement inquiries, please contact reimbursement.usa@polymedics.com.